In Phase A, individuals will get different doses and schedules of oral ABBV-744 tablet to recognize Harmless dosing regimen. Added contributors will likely be enrolled within the identified monotherapy dosign regimen. In Section B, members will obtain oral ruxolitinib and ABBV-744 might be given as "incorporate-on" therapy. In Section C, https://traudls999fqb2.blogpixi.com/profile